Byoong Yong Choi1, Hye Jin Oh2, Yun Jong Lee3, Yeong Wook Song4. 1. Department of Internal Medicine, Seoul Medical Center, Seoul, Korea. 2. Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea. 3. Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Korea. 4. Department of Internal Medicine, Seoul National University Hospital; and Department of Molecular Medicine and Biopharmaceutical Sciences, Medical Research Institute, Seoul National University College of Medicine, Seoul, Korea. ysong@snu.ac.kr.
Abstract
OBJECTIVES: Clinical features of primary Sjögren's syndrome (pSS) overlap with those of fibromyalgia (FM). This cross-sectional study was conducted to investigate the prevalence of FM in pSS patients and to compare the clinical features of pSS patients with FM to those without FM. METHODS: One hundred pSS patients were consecutively assessed to identify the presence of FM according to the American College of Rheumatology (ACR) 2010 criteria. Clinical and laboratory data were collected from all patients. Additional assessments included EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) and EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI). The severity of depression was measured by Hamilton depression rating scale 17-items (HAM-D scale). RESULTS: The prevalence of FM was 31.0% (31/100) in pSS. Widespread pain index and symptom severity scale were significantly correlated with ESSPRI (r=0.6542 and r=0.7173, both p<0.0001) and HAM-D scale (r=0.6734 and r=0.6471, both p<0.0001) in pSS. In multivariate analysis, ESSPRI and HAM-D scale were independently associated with increase of tender point count and symptom severity scale. ESSPRI was significantly higher in pSS patients with FM compared to those without FM (p<0.0001). The prevalence of FM in pSS patients with moderate-to-severe depression was significantly higher than those with mild depression or without depression (odds ratio= 10.62, p=0.0009). Serum 25-hydroxy vitamin D3 levels in pSS patients with FM were significantly (p=0.0072) decreased compared to those without FM. CONCLUSIONS: Our study showed that FM was prevalent in pSS. FM was associated with higher ESSPRI and more severe depression.
OBJECTIVES: Clinical features of primary Sjögren's syndrome (pSS) overlap with those of fibromyalgia (FM). This cross-sectional study was conducted to investigate the prevalence of FM in pSSpatients and to compare the clinical features of pSSpatients with FM to those without FM. METHODS: One hundred pSSpatients were consecutively assessed to identify the presence of FM according to the American College of Rheumatology (ACR) 2010 criteria. Clinical and laboratory data were collected from all patients. Additional assessments included EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) and EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI). The severity of depression was measured by Hamilton depression rating scale 17-items (HAM-D scale). RESULTS: The prevalence of FM was 31.0% (31/100) in pSS. Widespread pain index and symptom severity scale were significantly correlated with ESSPRI (r=0.6542 and r=0.7173, both p<0.0001) and HAM-D scale (r=0.6734 and r=0.6471, both p<0.0001) in pSS. In multivariate analysis, ESSPRI and HAM-D scale were independently associated with increase of tender point count and symptom severity scale. ESSPRI was significantly higher in pSSpatients with FM compared to those without FM (p<0.0001). The prevalence of FM in pSSpatients with moderate-to-severe depression was significantly higher than those with mild depression or without depression (odds ratio= 10.62, p=0.0009). Serum 25-hydroxy vitamin D3 levels in pSSpatients with FM were significantly (p=0.0072) decreased compared to those without FM. CONCLUSIONS: Our study showed that FM was prevalent in pSS. FM was associated with higher ESSPRI and more severe depression.
Authors: John A Gonzales; Annie Chou; Jennifer R Rose-Nussbaumer; Vatinee Y Bunya; Lindsey A Criswell; Caroline H Shiboski; Thomas M Lietman Journal: Am J Ophthalmol Date: 2018-04-12 Impact factor: 5.258
Authors: Kim D Jones; Terri Gelbart; Thomas C Whisenant; Jill Waalen; Tony S Mondala; David N Iklé; Daniel R Salomon; Robert M Bennett; Sunil M Kurian Journal: Clin Exp Rheumatol Date: 2016-02-12 Impact factor: 4.473
Authors: Katie L Hackett; Katherine H O Deane; Julia L Newton; Vincent Deary; Simon J Bowman; Tim Rapley; Wan-Fai Ng Journal: Arthritis Care Res (Hoboken) Date: 2018-05-21 Impact factor: 4.794